Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_assertion description "[As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_assertion evidence source_evidence_literature NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_assertion SIO_000772 22790962 NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_assertion wasDerivedFrom befree-20150227 NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_assertion wasGeneratedBy ECO_0000203 NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.
- befree-20150227 importedOn "2015-02-27" NP697593.RAZSri5kOkj_Jx2vpWhdbhE7JRov-T40bL5HeXAtbLFVE130_provenance.